MALAT1 and melanoma: First, we tested MALAT1-ASO treatment in a panel of twelve non-resistant melanoma cell lines, that have a variety of MAPK cancer-driving mutations (NRASQ61L, NRASQ61R, NRASQ61K, NRASG12D, NRASG12V, BRAFV600E and BRAFD594G), including two primary patient-derived cell lines (AV5 and Hs852T).